Companies

Company case studies with full pipeline analysis, plus the TPD competitive landscape.

Ask AI about this page

Company case studies

NASDAQ: KYMR

Kymera Therapeutics

Profile

Directed protein degradation to destroy disease

4 programs3 clinicalFounded 2016
:

Lila Sciences

Profile

Scientific Superintelligence

2 programsFounded 2023
NASDAQ: VRTX

Vertex Pharmaceuticals

Profile

Scientific innovation to create transformative medicines for serious diseases

7 programs7 clinicalFounded 1989

Competitive landscape

Sorted by therapeutic area overlap and clinical stage

ImmunologyOncologyNeurology6 companies
Ask AI
AR
Arvinas
ARVN
Ph 3
OncologyNeurology

PROTAC® Technology · 3 clinical programs

ARV-471 (Vepdegestrant)·ER+/HER2- Breast CancerPh 3
ARV-110 (Bavdegalutamide)·Metastatic Castration-Resistant Prostate CancerPh 2
ARV-102·Parkinson's DiseasePh 1
Ask AI
C4
C4 Therapeutics
CCCC
1/2
Oncology

TORPEDO® · 3 clinical programs

CFT8919·EGFR L858R NSCLC1/2
CFT1946·BRAF V600X Solid TumorsPh 1
CFT7455·Relapsed/Refractory MM / NHL1/2
Ask AI
NU
Nurix Therapeutics
NRIX
Ph 1
Oncology

DELigase™ · 2 clinical programs

NX-5948·B-cell Malignancies / CLL / MCLPh 1
NX-2127·Relapsed/Refractory B-cell MalignanciesPh 1
Ask AI
MO
Monte Rosa Therapeutics
GLUE
Ph 1
Oncology

QuEEN® · 2 clinical programs

MRT-2359·MYC-Driven Cancers (NSCLC, SCLC)Ph 1
MGX-12·Solid Tumors (Treg depletion)Ph 1
Ask AI
PL
Plexium
Private
Ph 1
Oncology

Molecular Glue Discovery · 1 clinical program

PLX-4545·Solid TumorsPh 1
Ask AI
VI
Vividion Therapeutics
Bayer (2021)
Pre
Oncology

Chemoproteomics-guided TPD · 0 clinical programs

VVD-159·OncologyPre
Ask AI
Data sources:Company investor materialsClinicalTrials.govSEC filingsPress releasesInteractive TPD matrix
Ask AI